Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Associated Therapies: -

Clinical Trials

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: Akt Inhibitor MK2206
Drug: Bendamustine Hydrochloride
Other: Laboratory Biomarker Analysis
Biological: Rituximab

First Posted Date: 2011-06-09

Last Posted Date: 2017-09-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT01369849

Locations: 🇺🇸
Metro-Minnesota NCI Community Oncology Research Program, Saint Louis Park, Minnesota, United States
🇺🇸
Minnesota Oncology and Hematology PA-Woodbury, Woodbury, Minnesota, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

and more 41 locations

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
B-Cell Non-Hodgkin's Lymphoma

Interventions: Drug: Bendamustine
Drug: Pentostatin
Drug: Ofatumumab

First Posted Date: 2011-05-11

Last Posted Date: 2018-05-25

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 10

Registration Number: NCT01352312

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Phase 3

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Obinutuzumab
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2011-04-11

Last Posted Date: 2022-08-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1401

Registration Number: NCT01332968

Locations: 🇨🇦
North York General Hospital, Toronto, Ontario, Canada
🇦🇺
St Vincent'S Hospital; Haematology, Fitzroy, Victoria, Australia
🇨🇦
Humber River Hospital, Toronto, Ontario, Canada

and more 180 locations

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Phase 1

Completed

Conditions: Anaplastic Large Cell Lymphoma
Chronic Lymphocytic Leukemia
Adult B Acute Lymphoblastic Leukemia
Adult Nasal Type Extranodal NK/T-Cell Lymphoma
Adult Solid Neoplasm
Lymphomatous Involvement of Non-Cutaneous Extranodal Site
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Hodgkin Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Angioimmunoblastic T-Cell Lymphoma

Interventions: Drug: Bendamustine Hydrochloride
Other: Pharmacological Study
Biological: Rituximab
Drug: Veliparib

First Posted Date: 2011-03-31

Last Posted Date: 2019-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT01326702

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

Phase 1

Completed

Conditions: B-cell Small Lymphocytic Lymphoma Recurrent

Interventions: Drug: TRU-016
Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2011-03-17

Last Posted Date: 2017-06-28

Lead Sponsor: Aptevo Therapeutics

Target Recruit Count: 12

Registration Number: NCT01317901

Locations: 🇺🇸
Site Reference ID/Investigator# 61523, Omaha, Nebraska, United States
🇺🇸
Site Reference ID/Investigator# 61542, Augusta, Georgia, United States
🇺🇸
Site Reference ID/Investigator# 61522, Hackensack, New Jersey, United States

and more 3 locations

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Bendamustine
Drug: Bortezomib

First Posted Date: 2011-03-15

Last Posted Date: 2018-02-07

Lead Sponsor: NYU Langone Health

Target Recruit Count: 24

Registration Number: NCT01315873

Locations: 🇺🇸
New York University Langone Medical Center, New York, New York, United States

A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

Phase 1

Completed

Conditions: Lymphocytic Leukemia, Chronic

Interventions: Drug: Fludarabine
Drug: Bendamustine
Drug: Obinutuzumab
Drug: Cyclophosphamide

First Posted Date: 2011-02-21

Last Posted Date: 2017-02-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 41

Registration Number: NCT01300247

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Biological: Ofatumumab
Drug: Bendamustine

First Posted Date: 2011-02-11

Last Posted Date: 2018-08-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT01294579

Locations: 🇺🇸
Novartis Investigative Site, Yakima, Washington, United States

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Phase 2

Active, not recruiting

Conditions: Ann Arbor Stage III Grade 1 Follicular Lymphoma
Ann Arbor Stage III Grade 3 Follicular Lymphoma
Ann Arbor Stage III Grade 2 Follicular Lymphoma
Grade 3a Follicular Lymphoma
Ann Arbor Stage IV Grade 1 Follicular Lymphoma
Ann Arbor Stage IV Grade 2 Follicular Lymphoma
Ann Arbor Stage IV Grade 3 Follicular Lymphoma

Interventions: Drug: Bendamustine Hydrochloride
Radiation: Fludeoxyglucose F-18
Drug: Bortezomib
Other: Laboratory Biomarker Analysis
Biological: Ofatumumab
Procedure: Positron Emission Tomography with Radiolabeled Targeting Agent

First Posted Date: 2011-01-31

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 135

Registration Number: NCT01286272

Locations: 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Saint Helena Hospital, Saint Helena, California, United States

and more 93 locations

GIMEMA CLL0809 Study (BendOfa)

Phase 2

Completed

Conditions: Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines
Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or

Interventions: Drug: Ofatumumab
Drug: Bendamustine

First Posted Date: 2010-11-19

Last Posted Date: 2019-01-25

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 49

Registration Number: NCT01244451

Locations: 🇮🇹
Azienda Sanitaria di Bolzano - Ospedale Centrale - Ematologia e Centro TMO, Bolzano, Italy
🇮🇹
Messina Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti "Papardo Piemonte", Messina, Italy
🇮🇹
Policlinico di Careggi, Università delgi studi di Firenze, Firenze, Italy

and more 29 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy